8 completed, 1 active not recruiting. 9 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 8, Active not recruiting 1 |
Follow Recurrent Childhood Soft Tissue Sarcoma: new trials by email Literature Review of Recurrent Childhood Soft Tissue Sarcoma trials Research Report on Recurrent Childhood Soft Tissue Sarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan - Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 20 | 2018-06-05 | 2026-11-13 |
| Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) Olaparib - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 6 | 2017-09-14 | 2024-12-11 |
| Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma Cixutumumab, Laboratory Biomarker Analysis, Temsirolimus - Childhood Alveolar Soft Part Sarcoma, Childhood Angiosarcoma | Phase 2 | Completed | National Cancer Institute (NCI) | 46 | 2012-06-18 | 2018-12-11 |
| Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia Alisertib, Laboratory Biomarker Analysis, Pharmacological Study - Hepatoblastoma, Previously Treated Childhood Rhabdomyosarcoma | Phase 2 | Completed | Children's Oncology Group | 118 | 2011-02-01 | 2020-05-13 |
| Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors cixutumumab, laboratory biomarker analysis - Adult Rhabdomyosarcoma, Adult Synovial Sarcoma | Phase 2 | Completed | National Cancer Institute (NCI) | 116 | 2009-01-01 | 2015-03-30 |
| Trabectedin in Treating Young Patients With Recurrent or Refractory Soft Tissue Sarcoma or Ewing's Family of Tumors trabectedin, pharmacological study - Previously Treated Childhood Rhabdomyosarcoma, Recurrent Childhood Rhabdomyosarcoma | Phase 2 | Completed | Children's Oncology Group | 50 | 2008-01-01 | 2018-09-14 |
| Ixabepilone in Treating Young Patients With Refractory Solid Tumors ixabepilone - Adult Rhabdomyosarcoma, Adult Synovial Sarcoma | Phase 2 | Completed | National Cancer Institute (NCI) | 120 | 2006-04-01 | 2014-11-14 |
| Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment oxaliplatin - Childhood Central Nervous System Germ Cell Tumor, Childhood Extragonadal Germ Cell Tumor | Phase 2 | Completed | National Cancer Institute (NCI) | 180 | 2004-10-01 | 2013-06-05 |
| Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood imatinib mesylate, laboratory biomarker analysis, pharmacological study - Childhood Desmoplastic Small Round Cell Tumor, Childhood Synovial Sarcoma | Phase 2 | Completed | National Cancer Institute (NCI) | 100 | 2002-05-01 | 2015-04-15 |
Neuroectodermal Tumors, Primitive, Peripheral (8) · Neuroblastoma (7) · Osteosarcoma (7) · Hepatoblastoma (5) · Rhabdomyosarcoma (4) · Sarcoma (4) · Wilms Tumor (4) · Familial ependymoma (3) · Adrenocortical Carcinoma (2) · Central Nervous System Neoplasms (2) · Ependymoma (2) · Glioma (2) · Histiocytosis, Langerhans-Cell (2) · Lymphoma, Non-Hodgkin (2) · Medulloblastoma (2)
Neoplasms (9) · Neoplasms by Histologic Type (9) · Neoplasms, Germ Cell and Embryonal (9) · Neoplasms, Glandular and Epithelial (9) · Neoplasms, Nerve Tissue (9) · Neoplasms, Neuroepithelial (9) · Neuroectodermal Tumors, Primitive (9) · Neoplasms, Bone Tissue (8) · Neoplasms, Connective Tissue (8) · Neoplasms, Connective and Soft Tissue (8) · Neuroectodermal Tumors (8) · Neoplasms, Complex and Mixed (6) · Female Urogenital Diseases (5) · Female Urogenital Diseases and Pregnancy Complications (5) · Kidney Diseases (5)
cixutumumab (2) · Biopsy (1) · Imatinib Mesylate (1) · MLN 8237 (1) · Magnetic Resonance Spectroscopy (1) · Nuclear Medicine Department, Hospital (1) · Oxaliplatin (1) · Phantoms, Imaging (1) · Sirolimus (1) · Specimen Handling (1) · Trabectedin (1) · X-Rays (1) · erdafitinib (1) · ixabepilone (1) · olaparib (1)
National Cancer Institute (NCI) (7) · Children's Oncology Group (2)
United States (9) · Canada (4) · Puerto Rico (2) · Australia (1)
Alice Lee (1) · Brenda Weigel, MD (1) · Brigitte Widemann (1) · Julia Glade-Bender (1) · Lars Wagner (1) · Mason Bond (1) · Orren Beaty (1) · Sylvain Baruchel, MD (1) · Yael Mosse (1)
PMID 31401903, PMID 22088484, PMID 30777875, PMID 34435684, PMID 38815151
U10CA098543 (7), U10CA180886 (2), UM1CA081457 (1)